Abrax has partnered with Vivotecnia, a CRO headquartered in Spain, to conduct toxicity studies on our prototype formulation, ABX-919 to confirm its safety in a GLP mini pig dermal toxicity study. Compliant with ISO9001:2008, Vivotecnia ensures that our critical development process is carried out to the highest quality standards with its highly qualified and experienced research management team both in the pharmaceutical and CRO industries.

Following this test, Abrax will quickly advance to a POC clinical trial to be conducted in Australia.

For more information on Vivotacnia, please click here.

We will update you on the progress of the trial in a subsequent press release.